Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Young woman suffering from itching on her skin and scratching an itchy place. Allergic reaction to insect bites, dermatitis, food, drugs. Health care concept. Allergy rash - Image
Organovo's candidate shows better pruritus data than others in its class.

The idea of an FXR agonist being the solution for treating metabolic function-associated steatohepatitis (MASH) took a substantial hit when Intercept Pharmaceuticals, Inc. ended development of obeticholic acid (OCA) in the disease. However, Organovo Holdings, Inc. has now reported Phase II data for an FXR agonist that shows hepatic fat-reducing ability as well as a cleaner safety and tolerability profile than typically seen with the drug class.

Key Takeaways
  • Organovo, which uses its bioprinting capabilities to produce 3D disease models, reported Phase II data in MASH that looks competitive compared to other FXR agonists.

Previously focused on bioprinting, research tools and tissue for direct therapy, Organovo in recent years has used its ability to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By 

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By 

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By 

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.